The characteristics of anhedonia in depression: a review from a clinically oriented perspective DOI Creative Commons
Congchong Wu, Qingli Mu, Weijia Gao

et al.

Translational Psychiatry, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 21, 2025

Anhedonia, as one of the core symptoms major depressive disorder (MDD), has been regarded a potential endophenotype disease. Multiple studies have evaluated mechanisms anhedonia in MDD, and found that MDD patients with showed different functions clinical features. In this review, we focus on research to explore differences between without manifestations biological alterations, elaborate treatments prognosis anhedonia. It is demonstrated associated adverse outcomes including more severe episode suicidality, poor MDD. At level, seem present higher levels inflammatory factors, abnormal metabolic function hypermetabolism BDNF. brain imaging studies, there are some structural and/ or functional changes multiple regions subcortical cortical areas, well limbic system Meanwhile, preliminary findings also indicated associations intestinal flora imbalance Moreover, evidence benefit selective serotonin reuptake inhibitors seemed limited anhedonia, other psychotherapy, physical therapy probiotic interventions remained be explored but interesting potential. Therefore, increased awareness anhedonic unique features would improved early diagnosis therapeutic effects

Language: Английский

Immune targets for therapeutic development in depression: towards precision medicine DOI Creative Commons
Wayne C. Drevets, Gayle Wittenberg, Edward T. Bullmore

et al.

Nature Reviews Drug Discovery, Journal Year: 2022, Volume and Issue: 21(3), P. 224 - 244

Published: Jan. 17, 2022

Over the past two decades, compelling evidence has emerged indicating that immune mechanisms can contribute to pathogenesis of major depressive disorder (MDD) and drugs with primary targets improve symptoms. Patients MDD are heterogeneous respect symptoms, treatment responses biological correlates. Defining a narrower patient group based on biology could increase response rates in certain subgroups: advance clinical psychiatry. For example, patients elevated pro-inflammatory biomarkers less likely respond conventional antidepressant drugs, but novel immune-based therapeutics potentially address their unmet needs. This article outlines framework for developing targeting subtype within reviews current state neuroimmune drug development mood disorders. We discuss causal role depression, together under investigation randomized controlled trials, biomarker elucidating link neural mechanisms, phenotypic selection strategies, need among MDD.

Language: Английский

Citations

200
Dopamine, Immunity, and Disease DOI Creative Commons

Breana Channer,

Stephanie Matt,

Emily Nickoloff-Bybel

et al.

Pharmacological Reviews, Journal Year: 2022, Volume and Issue: 75(1), P. 62 - 158

Published: Dec. 8, 2022

The neurotransmitter dopamine is a key factor in central nervous system (CNS) function, regulating many processes including reward, movement, and cognition. Dopamine also regulates critical functions peripheral organs, such as blood pressure, renal activity, intestinal motility. Beyond these functions, growing body of evidence indicates that an important immunoregulatory factor. Most types immune cells express receptors other dopaminergic proteins, take up, produce, store, and/or release dopamine, suggesting immunomodulation for function. Targeting pathways could be promising avenue the treatment inflammation disease, but despite increasing research this area, data on specific effects disease remain inconsistent poorly understood. Therefore, review integrates current knowledge role cell function inflammatory signaling across systems. We discuss understanding regulation CNS tissues, highlighting diseases Parkinson’s several neuropsychiatric conditions, neurologic human immunodeficiency virus, bowel rheumatoid arthritis, others. Careful consideration given to influence experimental design results, we note number areas need further research. Overall, our immunology at cellular, tissue, level prompts development therapeutics strategies targeted toward ameliorating through immunity.

Significance Statement

Canonically, recognized involved cognition, reward. However, acts modulator periphery. This comprehensively assesses pathogenesis cellular tissue level. will provide broad access information fields, identify investigation, drive therapeutic strategies.

Language: Английский

Citations

146
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review DOI Creative Commons
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam

et al.

Current Neuropharmacology, Journal Year: 2023, Volume and Issue: 22(4), P. 557 - 635

Published: May 3, 2023

Abstract: This narrative state-of-the-art review paper describes the progress in understanding and treatment of Posttraumatic Stress Disorder (PTSD). Over last four decades, scientific landscape has matured, with many interdisciplinary contributions to its diagnosis, etiology, epidemiology. Advances genetics, neurobiology, stress pathophysiology, brain imaging have made it apparent that chronic PTSD is a systemic disorder high allostatic load. The current state includes wide variety pharmacological psychotherapeutic approaches, which are evidence-based. However, myriad challenges inherent disorder, such as individual barriers good outcome, comorbidity, emotional dysregulation, suicidality, dissociation, substance use, trauma-related guilt shame, often render response suboptimal. These discussed drivers for emerging novel including early interventions Golden Hours, interventions, medication augmentation use psychedelics, well targeting nervous system. All this aims improve symptom relief clinical outcomes. Finally, phase orientation recognized tool strategize position step progression pathophysiology. Revisions guidelines systems care will be needed incorporate innovative treatments evidence emerges they become mainstream. generation well-positioned address devastating disabling impact traumatic events through holistic, cutting-edge efforts research.

Language: Английский

Citations

94
New and emerging approaches to treat psychiatric disorders DOI
Katherine W. Scangos, Matthew W. State, Andrew H. Miller

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(2), P. 317 - 333

Published: Feb. 1, 2023

Language: Английский

Citations

70
Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder DOI Creative Commons
Yun‐Ai Su, Tianmei Si

General Psychiatry, Journal Year: 2022, Volume and Issue: 35(1), P. e100724 - e100724

Published: Feb. 1, 2022

There is an increasing heavy disease burden of major depressive disorder (MDD) globally. Both high diagnostic heterogeneity and complicated pathological mechanisms MDD pose significant challenges. much evidence to support anhedonia as a core feature MDD. In the Diagnostic Statistical Manual Mental Disorders, Fifth Edition, further emphasised key item in diagnosis depression with melancholic features. Anhedonia multifaceted symptom that includes deficits various aspects reward processing, such anticipatory anhedonia, consummatory decision-making anhedonia. expected become important clinicopathological sign for predicting treatment outcome assisting clinical decision making. However, precise neurobiological are not clearly understood. this paper, we reviewed (1) current understanding link between MDD; (2) biological basis mechanism (3) challenges research on A more in-depth associated will improve diagnosis, prediction, patients future.

Language: Английский

Citations

47
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies DOI
Andrew H. Miller, Charles L. Raison

Molecular Psychiatry, Journal Year: 2022, Volume and Issue: 28(1), P. 68 - 75

Published: Dec. 2, 2022

Language: Английский

Citations

45
A role of gut–microbiota–brain axis via subdiaphragmatic vagus nerve in depression-like phenotypes in Chrna7 knock-out mice DOI Creative Commons
Yong Yang, Akifumi Eguchi, Xiayun Wan

et al.

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2022, Volume and Issue: 120, P. 110652 - 110652

Published: Sept. 30, 2022

Language: Английский

Citations

39
Annual Research Review: Neuroimmune network model of depression: a developmental perspective DOI Creative Commons
Robin Nusslock, Lauren B. Alloy, Gene H. Brody

et al.

Journal of Child Psychology and Psychiatry, Journal Year: 2024, Volume and Issue: 65(4), P. 538 - 567

Published: March 1, 2024

Depression is a serious public health problem, and adolescence an ‘age of risk’ for the onset Major Depressive Disorder. Recently, we others have proposed neuroimmune network models that highlight bidirectional communication between brain immune system in both mental physical health, including depression. These draw on research indicating cellular actors (particularly monocytes) signaling molecules cytokines) orchestrate inflammation periphery can directly modulate structure function brain. In brain, inflammatory activity heightens sensitivity to threats cortico‐amygdala circuit, lowers rewards cortico‐striatal alters executive control emotion regulation prefrontal cortex. When dysregulated, particularly under conditions chronic stress, generate feelings dysphoria, distress, anhedonia. This initiate unhealthy, self‐medicating behaviors (e.g. substance use, poor diet) manage which further heighten inflammation. Over time, dysregulation these circuits response may compound each other form positive feedback loop, whereby one organ exacerbates other. We suggest this dynamic joint vulnerability depression, during adolescence. three goals present paper. First, extend developmental framework risk depression Second, examine how perspective help explain high rates comorbidity psychiatric disorders across development, multimorbidity stress‐related medical illnesses. Finally, consider identifying pathways facilitate ‘next generation’ behavioral biological interventions target treat, ideally prevent, youth adolescents.

Language: Английский

Citations

10
Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry DOI
Andrew H. Miller, Michael Berk,

Gilles Bloch

et al.

Brain Behavior and Immunity, Journal Year: 2025, Volume and Issue: 125, P. 319 - 329

Published: Jan. 18, 2025

Language: Английский

Citations

1
Inflammation, Dopaminergic Brain and Bilirubin DOI Open Access
Sri Jayanti, Camilla Dalla Verde, Claudio Tiribelli

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(14), P. 11478 - 11478

Published: July 14, 2023

Dopamine is a well-known neurotransmitter due to its involvement in Parkinson’s disease (PD). not only involved PD but also controls multiple mental and physical activities, such as the pleasure of food, friends loved ones, music, art, mood, cognition, motivation, fear, affective disorders, addiction, attention deficit disorder, depression, schizophrenia. Dopaminergic neurons (DOPAn) are susceptible stressors, inflammation recognized risk for neuronal malfunctioning cell death major neurodegenerative diseases. Less known non-neurodegenerative conditions. Among endogenous defenses, bilirubin, heme metabolite, has been shown possess important anti-inflammatory activity and, most importantly, prevent DOPAn demise an ex vivo model by acting on tumor necrosis factor-alpha (TNFα). This review summarizes evidence linking DOPAn, (when possible, specifically TNFα), bilirubin order understand what known, gaps that need filling, hypotheses strategies preserve dopamine homeostasis with included.

Language: Английский

Citations

18